

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of: **Stamler, Loscalzo and Folts**

Application No.: **Not Yet Assigned**

Filed: **August 25, 2003**

For: **Use Of Nitric Oxide Adducts**

Attorney Docket No: **102258.121 US3**

Commissioner of Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants bring to the Examiner's attention the documents listed on the attached PTO-1449 Form and the following:

1. The Protest under 37 C.F.R. § 1.291(a) filed on March 31, 1999, in US Application No. 08/460,465. US Application No. 08/460,465 was filed June 2, 1995, and issued on July 11, 2000, as US Patent No. 6,087,479. The present application claims priority to U.S. Application No. 08/460,465.
2. The Protest under 37 C.F.R. § 1.291(a) filed on March 31, 1999, in US Application No. 08/438,418. US Application No. 08/438,418 was filed May 10, 1995, and issued on July 3, 2001, as US Patent No. 6,255,277.
3. The Response to Protest under 37 C.F.R. § 1.291(a) filed on August 13, 1999, in US Application No. 08/438,418.
4. The Information Disclosure Statement filed on August 13, 1999, in US Application No. 08/438,418.

Applicants respectfully submit that the Protest filed in US Application No. 08/460,465 and the Protest filed in US Application No. 08/438,418 do not have any bearing on the patentability of the claims in the present application. In support thereof, Applicants refer to the Information Disclosure Statement and Response to Protest filed on August 13, 1999, in US Application No. 08/438,418.


The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art.

## Information Disclosure Statement

Pursuant to 37 C.F.R. § 1.98(d), the documents listed on the attached PTO-1449 form are not being submitted herewith since they were previously cited and/or submitted in the parent (10/253,977) and/or grandparent (09/621,610) and/or great grandparent (09/433,550) and/or great, great grandparent (08/460,465) applications to which the present application claims priority.

This Information Disclosure Statement is being filed with the application. Accordingly, no fee is due.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Edward D. Grieff", is written over the typed name and registration number. The signature is stylized with large loops and a long horizontal stroke.

Edward D. Grieff  
Registration No. 38,898

Date: August 25, 2003

HALE AND DORR LLP  
1455 Pennsylvania Avenue, NW  
Washington, DC 20004  
Phone: (202) 942-8400



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	
				Filing Date	
				First Named Inventor	Stamler
				Group Art Unit	
				Examiner Name	
Sheet	1	of	3	Attorney Docket Number	102258.121 US2

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box



Approved  use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	
				<b>Filing Date</b> HEREWITH	
				<b>First Named Inventor</b> Stamler	
				<b>Group Art Unit</b>	
				<b>Examiner Name</b>	
<b>Sheet</b>	<b>2</b>	<b>of</b>	<b>3</b>	<b>Attorney Docket Number</b> 102258.121	

<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>			
<b>Examiner Initials*</b>	<b>Cite No.<sup>1</sup></b>	<b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>	<b>T<sup>2</sup></b>
		Stamler et al, Proc. Natl. Acad. Sci. USA, 89(1):444-448 (1992).	
		EPO Communication for EP 94 92 9143 (September 20, 1999).	
		Paape et al, Federation Proceedings, 44(3):449 (1985).	
		Simon et al, Arteriosclerosis and Thrombosis, 13(6):791-799 (June 1993).	
		Hollman et al, Circulation, 68(4):725-732 (1983).	
		Nishimura et al, Am. J. Physiol., 261(1):H15-H21 (1991).	
		Sullivan et al, Thromb. Haemostasis, 44(2):76-80 (1980).	
		Dembinska-Kiec et al, Int. J. Tiss. React., 15(2):55-64 (1993).	
		Darius et al, J. Cardiovasc. Pharmacol., 6(1):115-121 (1984).	
		Nishikawa et al, J. Pharmacol. Exp. Ther., 220(1):183-190 (1982).	
		Kolansky et al, Cardiovasc. Clin. 23:277-291 (1992).	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**Complete if Known****Applicati n Number****Filing Date**

**First Named Inventor**

Stamler	
---------	--

### Group Art Unit

**Examiner Name**

Attorney Docket Number

102258.121

Sheet

3

of

3

[illegible]

Examiner  
Signature

Date \_\_\_\_\_

**Considered**

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.